Open AccessThe Role of Topotecan in the Treatment of Small Cell Lung Cancer
Author(s) -
Brahmer Julie R.,
Ettinger David S.
Publication year - 1998
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.3-1-11
Subject(s) - topotecan , medicine , oncology , chemotherapy , paclitaxel , disease , lung cancer , radiation therapy , refractory (planetary science) , drug , pharmacology , astrobiology , physics
Topotecan is a chemotherapeutic agent that is active in the treatment of small cell lung cancer (SCLC). As a first‐line agent in chemotherapy‐naive patients with extensive disease SCLC, topotecan has a 39% response rate. As a second‐line drug in SCLC patients with “sensitive” disease and “refractory” disease, the response rate is greater than 38% and less than 10%, respectively. The combination of topotecan and paclitaxel exhibits a promising overall response rate of 92% in chemotherapy‐naive patients with extensive disease SCLC. Further studies are warranted with topotecan used in combination with other agents, including radiation therapy in patients with SCLC.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom